粪菌移植治疗溃疡性结肠炎：一种不断发展的疗法。
Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy.
作者信息
Sood Ajit, Singh Arshdeep, Midha Vandana, Mahajan Ramit, Kao Dina, Rubin David T, Bernstein Charles N
机构信息
Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India.
Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India.
出版信息
Crohns Colitis 360. 2020 Aug 15;2(4):otaa067. doi: 10.1093/crocol/otaa067. eCollection 2020 Oct.
BACKGROUND
Fecal microbiota transplantation (FMT) is currently an approved treatment for recurrent and refractory Clostridioides difficile infection. However, its use in ulcerative colitis is at an early stage and significant gaps remain in our understanding of the mechanisms and logistics of its practical application.
METHODS AND RESULTS
This article aims to look into specific issues which remain unsettled for use of FMT in ulcerative colitis including donor and recipient selection, route of administration, and duration of therapy. We also discuss optimal ways to assess response to FMT and the current state of FMT regulations. In addition, we postulate the impact of diet on the microbiome profile of the donor and recipient. We also suggest a change in the nomenclature from FMT to fecal microbiome transfer.
CONCLUSION
FMT is an evolving therapy. There are several considerations for its use in UC but its use and role should be directed by further clinical trials.
背景
粪便微生物群移植（FMT）目前是复发性和难治性艰难梭菌感染的一种获批治疗方法。然而，其在溃疡性结肠炎中的应用尚处于早期阶段，我们对其实际应用的机制和流程的理解仍存在重大差距。
方法与结果
本文旨在探讨FMT在溃疡性结肠炎应用中仍未解决的具体问题，包括供体和受体的选择、给药途径以及治疗持续时间。我们还讨论了评估FMT反应的最佳方法以及FMT监管的现状。此外，我们推测饮食对供体和受体微生物组谱的影响。我们还建议将术语从FMT改为粪便微生物组移植。
结论
FMT是一种不断发展的治疗方法。在溃疡性结肠炎中使用它有几个需要考虑的因素，但其使用和作用应由进一步的临床试验来指导。
Zotero 插件